You know, this is a really good point. Quarterly numbers are very important here, compared to year over year. Recent events have led me to be pretty nervous with BMRN, but in the long run I really dont see any problems. Short term, I could see us going lower especially if the conference call does not show a bright side of things. Well, actually, long term there are some problems as well... mainly a very limited pipeline.
My two main questions are: what is the cash for? what happened to sickle cell trial?
Hopefully the answers to both of these relieve my short and long term worries. I would definitely like to see the $20's again soon.
News 
Market Data 
Discover 
AI
